Carboplatin (CBDCA) plus etoposide (VP-16) in non small cell lung cancer (NSCLC) treatment - European Journal of Cancerdoi:10.1016/0959-8049(93)91532-PBernardo, G.Bernardo, A.Plastina, M.Strada, M.R.Brunetti, G.Pozzi, U.Rossi, A....
Lung Cancer Volume 11, Supplement 1, June 1994, Pages 101Abstract Therapy Chemotherapy/Small cellDose escalation study of carboplatin (CBDCA) and etoposide (VP-16) with G-CSF in small cell lung cancer (SCLC) : N. Katakami∗, M. Okazaki∗, Y. Ariyoshi, H. Ikegami, K. Furuse, M. ...
IMVP‐16aggressive non‐Hodgkin's lymphomarelapsed lymphomarefractory lymphomaThe purpose of this study was to determine the efficacy of salvage chemotherapy with, P-IMVP-16/CBDCA, consisting of carboplatin (CBDCA), etoposide (VP-16), ifosfamide (IFM), and methotrexate (MTX), for patients with ...
--> Abstract: The purpose of this study was to determine the efficacy of salvage chemotherapy with, P‐IMVP‐16/CBDCA, consisting of carboplatin (CBDCA), etoposide (VP‐16), ifosfamide (IFM), and methotrexate (MTX), for patients with aggressive non‐Hodgkin's lymphoma (NHL) who had ...
aged 70-80 or younger (but with poor ECOG PS) received a CBDCA + VP16 treatment, at a 4-week interval as follows: cycle 1: CBDCA = AUC 4; VP16 = 50 mg b.i.d. orally d 1-14); cycle 2: CBDCA = AUC 5; VP16 = 50 mg b.i.d. orally d 1-14; cycle 3: CBDCA = AUC ...
The chemotherapy was consisted of CBDCA (400 mg/mfor previously untreated pts or 350 mg/mfor previously treated pts on day 1) and VP-16 (l00 mgon days 1–3) every four weeks. If the nadir of platelet counts was < 75 × 10/ml in the observation cycle of chemotherapy, ...